首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1623610

阿茲海默症的治療和診斷：全球市場

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

出版日期: 2024年12月26日 | 出版商:

BCC Research | 英文 125 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球阿茲海默症治療和診斷市場規模預計將從2023年的90億美元和2024年的97億美元成長到2029年的196億美元，預測期內的年複合成長率為 15.1%。

AD 生物標記測試領域預計將從2024年的58億美元增至2029年的88億美元，預測期內年複合成長率為 8.7%。 AD藥物領域預計將從2024年的39億美元成長到2029年終的108億美元，年複合成長率為22.6%。

本報告調查了全球阿茲海默症治療和診斷市場，並提供了市場概況、市場影響因素和市場機會分析、法律制度、新興技術和技術發展趨勢、市場規模趨勢和預測，各種區分、各地區的詳細分析，競爭情況，主要企業簡介等彙整資料。

市場動態簡介
市場促進因素
AD 發生率增加
許多未滿足的需求
擴大關注診斷和藥物開發中的生物標記
增加神經科學的公共和私人投資
提高公眾意識和早期診斷
多種藥物進入後期臨床試驗
市場限制因素
診斷和新療法的高成本
品牌藥的專利到期和學名藥的出現
藥物研發失敗率高

第4章新興科技與發展

新興科技/趨勢
用於AD篩檢和診斷的血液檢測
緩解疾病的小分子藥物
重新利用藥物
人工智慧和機器學習
管道分析
概述
治療目的類型
第三階段開發中的新AD治療藥
依目標類型
依病情
開發中的新型PET放射性追蹤劑

第5章市場區隔分析

細分細分
市場分析：依測試類型
AD 生物標記測試市場：依測試類型
AD 治療藥物市場：依治療目的分類
AD 藥物市場：依藥物類別
AD 治療藥物市場：依藥物類型
AD 治療藥物市場：依疾病階段分類
地域分佈
市場分析：依地區
北美洲
歐洲
亞太地區
其他領域

第6章競爭訊息

AD治療藥物
阿茲海默症學名藥市場
阿茲海默症品牌藥物市場
Donepezil
Rivastigmine
Galantamine
Memantine
伴隨藥物（Memantine、Donepezil）
AD診斷劑
概述
AD診斷市場的產品上市/核准

第7章附錄

調查方法
來源
簡稱
公司簡介
ABBVIE INC.
ALPHA COGNITION
ALZPATH INC.
AUROBINDO PHARMA
BIOGEN
C2N DIAGNOSTICS
CORIUM LLC.
DIADEM SRL
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
HU GROUP HOLDINGS INC.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LILLY
OTSUKA HOLDINGS CO. LTD.
QUEST DIAGNOSTICS INC.

簡介目錄圖表

Product Code: PHM062E

The global market for Alzheimer’s disease therapeutics and diagnostics was valued at $9 billion in 2023. This market is expected to grow from $9.7 billion in 2024 to $19.6 billion by 2029, at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2029.

The global market for AD biomarker tests is expected to grow from $5.8 billion in 2024 to $8.8 billion by 2029, at a CAGR of 8.7% from 2024 to 2029.

The global market for AD therapeutics is expected to grow from $3.9 billion in 2024 to $10.8 billion by 2029, at a CAGR of 22.6% from 2024 to 2029.

Report Scope

This report focuses on the global market for Alzheimer's disease (AD) diagnostics and therapeutics, offering an updated review of this rapidly emerging market. In this report, the diagnostic market covers only biomarker tests for AD. Cognitive tests and neuroimaging diagnostic methods assessing structural changes are not part of the market calculations. The diagnostics market segmentation is based on the test type and region.

The therapeutics segment covers pharmacological treatments (drugs) only. This report does not cover alternative treatment options, such as procedural interventions. Additionally, many medications are used "off-label" to manage non-cognitive symptoms, such as agitation and depression, associated with dementia due to AD. This report does not cover off-label drugs used in the treatment of Alzheimer's. The therapeutics market segmentation is based on purpose, drug class, drug type, disease stage, and region.

An analysis of clinical trials, innovations, opportunities, and the latest trends in the AD diagnostics and therapeutics market are also discussed in the report.

Report Includes

38 data tables and 80 additional tables
Analyses of the trends in the global market for Alzheimer's disease (AD) therapeutics and diagnostics, with market revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecasts for 2024-2025, and projected CAGRs through 2029
Estimates of the size of the global market and revenue growth prospects, along with a market share analysis by type, therapeutic application, drug classification, mechanism of action, disease state of indication and region
Facts and figures pertaining to key market dynamics, technological advances, regulations, and the impact of macroeconomic factors
Identification of diagnostic tools and equipment; scientific and technological frameworks; drug profiles, clinical groundworks; and coverage of global developments
Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease, as well as the promising new drug candidates and diagnostic imaging agents
An analysis of patents, emerging trends and the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Profiles of leading companies, including AbbVie Inc., Biogen, Eisai Co. Ltd., Eli Lilly and Co., and F. Hoffmann-La Roche Ltd.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Alzheimer's Disease Overview
Alzheimer's Disease Pathophysiology
AD and Amyloid Cascade
AD and Tauopathy
AD and Neurotransmitter Systems
Diagnosis of AD
Cognitive Status Testing
Brain Imaging
Lumbar Puncture
Blood-Biomarker Tests
Genetic Testing
Pharmaceutical Treatment of AD

Chapter 3 Market Dynamics

Market Dynamics Snapshot
Market Drivers
Growing Incidence of AD
High Unmet Need
Growing Focus on Biomarkers in Diagnosis and Drug Development
Increasing Public and Private investment in Neuroscience
Growing Public Awareness and Early Diagnosis
Large Number of Drugs in Late-Stage Clinical Trials
Market Restraints
High Costs of Diagnostics and Novel Therapies
Patent Expirations of Branded Drugs and Emergence of Generics
High Failure Rate in Drug Development

Chapter 4 Emerging Technologies and Developments

Emerging Technologies/Trends
Blood Tests for AD Screening and Diagnosis
Disease Modifying Small-Molecule Drugs
Re-purposed Drugs
AI and Machine Learning
Pipeline Analysis
Overview
Therapeutic Purpose Type
Novel AD Therapeutics in Development in Phase 3
By Target Type
By Disease State
Novel PET Radiotracers in Development

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Market Analysis, by Test Type
AD Biomarker Tests Market, by Test Type
AD Therapeutics Market, by Therapeutic Purpose
AD Therapeutics Market, by Drug Class
AD Therapeutics Market, by Drug Type
AD Therapeutics Market, by Disease Stage
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Chapter 6 Competitive Intelligence

AD Therapeutics
Alzheimer's Generic Drug Market
Alzheimer's Branded Drug Market
Donepezil
Rivastigmine
Galantamine
Memantine
Combination Therapy (Memantine and Donepezil)
AD Diagnostics
Overview
Product Launches/Approvals in the AD Diagnostics Market

Chapter 7 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ALPHA COGNITION
ALZPATH INC.
AUROBINDO PHARMA
BIOGEN
C2N DIAGNOSTICS
CORIUM LLC.
DIADEM SRL
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
H.U. GROUP HOLDINGS INC.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LILLY
OTSUKA HOLDINGS CO. LTD.
QUEST DIAGNOSTICS INC.

簡介目錄圖表

List of Tables

Summary Table : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 1 : Brain Imaging Technologies and Application in the Alzheimer's Context
Table 2 : Common Methods for AD Detection
Table 3 : Key Clinical Biomarkers Used in the Diagnosis of AD
Table 4 : NIH Funding Estimates for Alzheimer's Disease Research, 2017-2024
Table 5 : Selected AD Biomarker-Focused Consortia
Table 6 : Recent Therapeutic Programs Ceased Due to Failure in Clinical Trials
Table 7 : Selected Blood Tests in Development for AD Screening/Diagnosis
Table 8 : Disease Modifying Small Molecules AD Drug Candidates in Phase 3 Clinical Trials
Table 9 : Disease Modifying Large Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 10 : Treatments for AD-Related Neuropsychiatric and Behavioral Symptoms in Phase 3 Clinical Trials
Table 11 : Cognitive Enhancer AD Drug Candidates in Phase 3 Clinical Trials
Table 12 : Radiopharmaceuticals for CNS Imaging in Clinical Development
Table 13 : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 14 : Comparison of Biomarker Tests
Table 15 : FDA-Approved PET Radiopharmaceuticals for AD Diagnosis
Table 16 : CSF-Based IVD Tests for AD
Table 17 : Blood Tests for AD Diagnosis
Table 18 : Global Market for AD Biomarker Tests, by Test Type, Through 2029
Table 19 : FDA-Approved Drugs to Treat Cognitive Symptoms of AD
Table 20 : FDA-Approved Drugs to Treat Non-Cognitive Symptoms of AD
Table 21 : Global Market for AD Therapeutics, by Therapeutic Purpose, Through 2029
Table 22 : FDA-Approved AChEIs
Table 23 : FDA-Approved Anti-Amyloid Antibodies
Table 24 : Selected Anti-Inflammatory and Neuroprotective Agents in Phase 3 Clinical Trials
Table 25 : Global Market for AD Therapeutics, by Drug Class, Through 2029
Table 26 : Anti-Amyloid Drugs in Phase 3 Clinical Development
Table 27 : Neurotransmitter Modulars in Clinical Trials Phase 3
Table 28 : Global Market for AD Therapeutics, by Drug Type, Through 2029
Table 29 : Patent Information for AD Drugs
Table 30 : Number of Companies with Active FDA Approval to Market AD drugs in the U.S.
Table 31 : FDA-Approved AD Drugs and Their Indications
Table 32 : Global Market for AD Therapeutics, by Disease Stage, Through 2029
Table 33 : Global Market for AD Therapeutics and Diagnostics, by Region, Through 2029
Table 34 : North American Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 35 : North American Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 36 : U.S. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 37 : Canadian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 38 : Mexican Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 39 : European Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 40 : Europe Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 41 : German Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 42 : French Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 43 : U.K. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 44 : Italian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 45 : Rest of European Countries' Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 46 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 47 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 48 : Chinese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 49 : Japanese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 50 : Rest of Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 51 : RoW Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 52 : Key Companies in the U.S. Alzheimer's Generic Drug Market
Table 53 : Commercially Available FDA-Approved Branded AD Drugs
Table 54 : Companies with Active FDA Approval to Market Donepezil in the U.S.
Table 55 : Companies with Active FDA Approval to Market Rivastigmine in the U.S.
Table 56 : Companies with Active FDA Approval to Market Galantamine in U.S.
Table 57 : Companies with Active FDA Approval to Market Memantine in the U.S.
Table 58 : Companies with Active FDA Approval to Market Combination Therapy (Memantine and Donepezil) in the U.S.
Table 59 : Selected Product Approvals/Launches in the AD Diagnostics Market, 2022-2024
Table 60 : Information Sources in this Report
Table 61 : Abbreviations Used in This Report
Table 62 : AbbVie Inc.: Company Snapshot
Table 63 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 64 : AbbVie Inc.: Product Portfolio
Table 65 : AbbVie Inc.: News/Key Developments, 2024
Table 66 : Alpha Cognition: Company Snapshot
Table 67 : Alpha Cognition: Financial Performance, FY 2022 and 2023
Table 68 : Alpha Cognition: Product Portfolio
Table 69 : Alpha Cognition: News/Key Developments, 2024
Table 70 : ALZpath Inc.: Company Snapshot
Table 71 : ALZpath Inc.: Product Portfolio
Table 72 : ALZpath Inc.: News/Key Developments, 2023 and 2024
Table 73 : Aurobindo Pharma: Company Snapshot
Table 74 : Aurobindo Pharma: Financial Performance, FY 2022 and 2023
Table 75 : Aurobindo Pharma: Product Portfolio
Table 76 : Aurobindo Pharma: News/Key Developments, 2023
Table 77 : Biogen: Company Snapshot
Table 78 : Biogen: Financial Performance, FY 2022 and 2023
Table 79 : Biogen: Product Portfolio
Table 80 : Biogen: News/Key Developments, 2023 and 2024
Table 81 : C2N Diagnostics: Company Snapshot
Table 82 : C2N Diagnostics: Product Portfolio
Table 83 : C2N Diagnostics: News/Key Developments, 2023 and 2024
Table 84 : Corium LLC.: Company Snapshot
Table 85 : Corium LLC.: Product Portfolio
Table 86 : Corium LLC.: News/Key Developments, 2022 and 2023
Table 87 : Diadem srl: Company Snapshot
Table 88 : Diadem srl: Product Portfolio
Table 89 : Diadem srl: News/Key Developments, 2022 and 2023
Table 90 : Eisai Co. Ltd.: Company Snapshot
Table 91 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 92 : Eisai Co. Ltd.: Product Portfolio
Table 93 : Eisai Co. Ltd.: News/Key Developments, 2022-2024
Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 98 : H.U. Group Holdings Inc.: Company Snapshot
Table 99 : H.U. Group Holdings Inc.: Financial Performance, FY 2022 and 2023
Table 100 : H.U. Group Holdings Inc.: Product Portfolio
Table 101 : H.U. Group Holdings Inc.: News/Key Developments, 2022-2024
Table 102 : Laboratory Corporation of America Holdings: Company Snapshot
Table 103 : Laboratory Corporation of America Holdings: Financial Performance, FY 2022 and 2023
Table 104 : Laboratory Corporation of America Holdings: Product Portfolio
Table 105 : Laboratory Corporation of America Holdings: News/Key Developments, 2022-2024
Table 106 : Lilly: Company Snapshot
Table 107 : Lilly: Financial Performance, FY 2022 and 2023
Table 108 : Lilly: Product Portfolio
Table 109 : Lilly: News/Key Developments, 2024
Table 110 : Otsuka Holdings Co. Ltd.: Company Snapshot
Table 111 : Otsuka Holdings Co. Ltd: Financial Performance, FY 2022 and 2023
Table 112 : Otsuka Holdings Co. Ltd: Product Portfolio
Table 113 : Otsuka Holdings Co. Ltd: News/Key Developments, 2023 and 2024
Table 114 : Quest Diagnostics Inc.: Company Snapshot
Table 115 : Quest Diagnostics Inc.: Financial Performance, FY 2022 and 2023
Table 116 : Quest Diagnostics Inc.: Product Portfolio
Table 117 : Quest Diagnostics Inc.: News/Key Developments, 2022-2024

List of Figures

Summary Figure : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 1 : Hypothetical Models for Progression of Alzheimer's Disease
Figure 2 : Market Dynamics of Alzheimer's Disease Therapeutics and Diagnostics
Figure 3 : Breakdown of Global Aging Population (65 or Older) with Alzheimer's-Associated Dementia, by Age Group, 2023
Figure 4 : Breakdown of Dementia Cases in Japan, by Disease Type
Figure 5 : Alzheimer's and Related Dementia Research Funding at the NIH, 2013-2023
Figure 6 : Potential Use of Blood-Based Biomarkers in Primary Care
Figure 7 : Novel Industry-Sponsored AD Therapeutic Agents in Clinical Development, by Clinical Trial Phase
Figure 8 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Type
Figure 9 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Subtype
Figure 10 : Number of AD Clinical Trials for Most Common Targets, by Phase, as of Oct. 2024
Figure 11 : Share of Active Clinical Trials for AD, by Disease State, as of Oct. 2024
Figure 12 : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 13 : Global Market Shares of AD Biomarker Tests, by Test Type, 2023
Figure 14 : Global Market Shares of AD Therapeutics, by Therapeutic Purpose, 2023
Figure 15 : Global Market Shares of AD Therapeutics, by Drug Class, 2023
Figure 16 : Global Market Shares of AD Therapeutics, by Drug Type, 2023
Figure 17 : Alzheimer's Disease (AD) Continuum
Figure 18 : Global Market Shares of AD Therapeutics, by Disease Stage, 2023
Figure 19 : Global Market for AD Therapeutics and Diagnostics, by Region, 2021-2029
Figure 20 : Global Market Shares of AD Therapeutics and Diagnostics, by Region, 2023
Figure 21 : North American Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 22 : North American Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 23 : European Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 24 : European Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 25 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 26 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 27 : RoW Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 28 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 29 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 30 : Aurobindo Pharma: Revenue Share, by Business Unit, FY 2023
Figure 31 : Aurobindo Pharma: Revenue Share, by Country/Region, FY 2023
Figure 32 : Biogen: Revenue Share, by Business Unit, FY 2023
Figure 33 : Biogen: Revenue Share, by Country/Region, FY 2023
Figure 34 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 35 : Eisai Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 36 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 37 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 38 : Laboratory Corporation of America Holdings: Revenue Share, by Business Unit, FY 2023
Figure 39 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 40 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 41 : Otsuka Holdings Co. Ltd: Revenue Share, by Business Unit, FY 2023
Figure 42 : Otsuka Holdings Co. Ltd: Revenue Share, by Country/Region, FY 2023
Figure 43 : Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2023